Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 2.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,373 shares of the company’s stock after selling 503 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Moderna were worth $2,657,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in MRNA. Cedar Wealth Management LLC raised its position in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Commerzbank Aktiengesellschaft FI lifted its position in shares of Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of Moderna by 21.6% in the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares during the last quarter. Claro Advisors LLC increased its position in shares of Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in Moderna by 32.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after purchasing an additional 116 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 689 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO James M. Mock sold 689 shares of Moderna stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares in the company, valued at $859,486.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total value of $1,756,200.00. Following the sale, the director now owns 2,269,015 shares in the company, valued at approximately $265,656,276.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,158 shares of company stock worth $11,167,312. Corporate insiders own 15.70% of the company’s stock.

Moderna Trading Down 3.4 %

MRNA opened at $65.69 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm has a market cap of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.67. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The business has a fifty day simple moving average of $90.07 and a 200-day simple moving average of $110.96.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.62) EPS. On average, equities analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Evercore ISI restated an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $100.44.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.